Results 1 to 10 of about 7,815 (192)

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor [PDF]

Discover Oncology
Background Synovial sarcoma (SS) is a rare soft tissue sarcoma (STS) with limited treatment options, indicating the need for novel therapeutic strategies.
Noritaka Honda, Hirokazu Taniguchi, Sawana Ono, Fumiko Hayashi, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Takahiro Takazono, Hiroshi Ishimoto, Noriho Sakamoto, Yasushi Obase, Mitsuko Masutani, Tomoya Nishino, Hiroshi Mukae   +13 more
doaj   +2 more sources

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Cancer Medicine, 2022
Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and paclitaxel. Methods
Marina N Sharifi, Ruth M O'Regan, Jens C Eickhoff   +2 more
exaly   +2 more sources

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents

Biomedicines, 2021
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted ...
Dong Zhou, Cedric Mpoy, Sadia Afrin
exaly   +3 more sources

Radiosensitization Effect of PARP Inhibitor Talazoparib Involves Decreasing Mitochondrial Membrane Potential and Induction of Cellular Senescence [PDF]

Current Issues in Molecular Biology
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) with radiation therapy can enhance the sensitivity of cancer cells by inhibiting DNA repair pathways.
Barkha Saraswat, Ankitha Vadi Velu, Zhongming Gao, Zongxiang Zhang, Haoyang Zhu, Ying Tong, Mitsuko Masutani   +6 more
doaj   +2 more sources

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis [PDF]

Therapeutic Advances in Medical Oncology
Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes.
Mingjun Rui, Yingcheng Wang, Qiran Wei, Joyce H. S. You   +3 more
doaj   +2 more sources

Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma [PDF]

Frontiers in Oncology
High-grade neuroendocrine carcinoma (NEC) of the rectum is a rare and aggressive malignancy, with limited treatment options and a poor prognosis. We report the successful off-label use of the PARP inhibitor talazoparib in a patient with metastatic ...
Milan Khealani, Byoung Uk Park, Robben Schat, Emmanuel S. Antonarakis, Arjun Gupta   +4 more
doaj   +2 more sources

A Phase I trial of talazoparib in patients with advanced hematologic malignancies [PDF]

International Journal of Hematologic Oncology, 2021
Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. Patients & methods: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy
Bloor, A, Chen, Y, Cotter, MJ, Gaymes, T, Gopal, AK, Juckett, M, Khwaja, A, Mattison, RJ, Menne, T, Mufti, GJ, Popat, R   +10 more
core   +5 more sources

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models [PDF]

Nature Communications
Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts
Joan Kyula-Currie, Victoria Roulstone, James Wright, Francesca Butera, Arnaud Legrand, Richard Elliott, Martin McLaughlin, Galabina Bozhanova, Dragomir Krastev, Stephen Pettitt, Tencho Tenev, Magnus Dillon, Shane Foo, Emmanuel C. Patin, Victoria Jennings, Charleen Chan Wah Hak, Elizabeth Appleton, Amarin Wongariyapak, Malin Pedersen, Antonio Rullan, Jyoti Choudhary, Chris Bakal, Pascal Meier, Christopher J. Lord, Alan Melcher, Kevin J. Harrington   +25 more
doaj   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107 [PDF]

Molecular Oncology
Advanced urothelial carcinoma (UC) requires new therapeutics beyond chemo‐ and immunotherapies. Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin‐treated UC, yielded limited response.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
doaj   +2 more sources

The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast [PDF]

Oncology and Therapy
Homologous recombination repair (HRR) is a DNA repair pathway that helps maintain genomic stability. About one quarter of patients with metastatic castration-resistant prostate cancer (mCRPC) have alterations in HRR genes.
Jennifer L. E. Lloyd, Julia Batten
doaj   +2 more sources